Biotech RadarJobs updated

COMPANY

Akamis Bio

HQ: Cambridge, MA source · akamisbio.com ↗

Clinical Phase 1

We are developing oncolytic immunotherapies to expand the treatment options for people living with colorectal cancer. From company website Source · Oct 13, 2026

Keywords: Epithelial Tumor Squamous Cell Carcinoma of the Head and Neck Locally Advanced Rectal Cancer Colorectal Cancer Recurrent Platinum Resistant Ovarian Cancer Resectable Colon Cancer Resectable Non-small Cell Lung Cancer Resectable Bladder Cancer Resectable Renal Cell Carcinoma Solid Tumours of Epithelial Origin Metastatic Colorectal Cancer Metastatic Bladder Cancer Cancer Cachexia NG-641 Enadenotucirev NG-350A Colo-Ad1 MT-102

Profile checked Oct 10, 2026

$60.0MRaised (2 yrs)11Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer source ↗
  2. Raise Private equity round — Series A: $60M (total, as published), announced Dec 17, 2024. Source: company's own press page. source ↗
  3. Trial start Phase 1: Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY) source ↗
  4. Trial start Phase 1: Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours source ↗
  5. Trial start Phase 1: A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck source ↗
  6. Trial start Phase 1: First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector source ↗
  7. Trial start Phase 1: First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) source ↗
  8. Trial start I: Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors source ↗
  9. Trial start I: Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients source ↗
  10. Trial start Phase 1: Mechanism of Action Trial of ColoAd1 source ↗
  11. Trial start I: Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients source ↗
  12. Trial start Phase 2: A Clinical Study With MT-102 in Subjects With Cancer Cachexia source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $60.0M. Last 2 years.

Clinical trials (lead sponsor) 11

RecordTitlePhaseStatusStartPrimary completion
NCT06459869NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal CancerPhase 1Active, not recruitingApr 7, 2025Dec 30, 2026 (estimated)
NCT05165433Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)Phase 1CompletedApr 13, 2022Aug 29, 2025 (actual)
NCT05043714Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial TumoursPhase 1CompletedDec 1, 2021Nov 13, 2023 (actual)
NCT04830592A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and NeckPhase 1CompletedNov 4, 2021Dec 7, 2023 (actual)
NCT04053283First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral VectorPhase 1CompletedJan 23, 2020Aug 31, 2023 (actual)
NCT03852511First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)Phase 1CompletedFeb 19, 2019Feb 4, 2022 (actual)
NCT02636036Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial TumorsICompletedJan 25, 2016Oct 8, 2021 (actual)
NCT02028117Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer PatientsICompleted2014-06Nov 19, 2019 (actual)
NCT02053220Mechanism of Action Trial of ColoAd1Phase 1Completed2013-062015-04 (actual)
NCT02028442Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer PatientsICompletedSep 20, 2012Apr 29, 2016 (actual)
NCT01238107A Clinical Study With MT-102 in Subjects With Cancer CachexiaPhase 2Completed2011-042013-05 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback